Your browser doesn't support javascript.
loading
Subjective cognitive complaints one year after ceasing adjuvant endocrine treatment for early-stage breast cancer.
Ribi, K; Aldridge, J; Phillips, K-A; Thompson, A; Harvey, V; Thürlimann, B; Cardoso, F; Pagani, O; Coates, A S; Goldhirsch, A; Price, K N; Gelber, R D; Bernhard, J.
Afiliação
  • Ribi K; IBCSG Coordinating Center, Effingerstr. 40, Bern 3008, Switzerland.
Br J Cancer ; 106(10): 1618-25, 2012 May 08.
Article em En | MEDLINE | ID: mdl-22531635
BACKGROUND: In the BIG 1-98 trial objective cognitive function improved in postmenopausal women 1 year after cessation of adjuvant endocrine therapy for breast cancer. This report evaluates changes in subjective cognitive function (SCF). METHODS: One hundred postmenopausal women, randomised to receive 5 years of adjuvant tamoxifen, letrozole, or a sequence of the two, completed self-reported measures on SCF, psychological distress, fatigue, and quality of life during the fifth year of trial treatment (year 5) and 1 year after treatment completion (year 6). Changes between years 5 and 6 were evaluated using the Wilcoxon signed-rank test. Subjective cognitive function and its correlates were explored. RESULTS: Subjective cognitive function and the other patient-reported outcomes did not change significantly after cessation of endocrine therapy with the exception of improvement for hot flushes (P=0.0005). No difference in changes was found between women taking tamoxifen or letrozole. Subjective cognitive function was the only psychosocial outcome with a substantial correlation between year 5 and 6 (Spearman's R=0.80). Correlations between SCF and the other patient-reported outcomes were generally low. CONCLUSION: Improved objective cognitive function but not SCF occur following cessation of adjuvant endocrine therapy in the BIG 1-98 trial. The substantial correlation of SCF scores over time may represent a stable attribute.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Tamoxifeno / Triazóis / Neoplasias da Mama / Cognição / Inibidores da Aromatase / Antagonistas de Estrogênios / Nitrilas Tipo de estudo: Clinical_trials Limite: Female / Humans Idioma: En Ano de publicação: 2012 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Tamoxifeno / Triazóis / Neoplasias da Mama / Cognição / Inibidores da Aromatase / Antagonistas de Estrogênios / Nitrilas Tipo de estudo: Clinical_trials Limite: Female / Humans Idioma: En Ano de publicação: 2012 Tipo de documento: Article